Clinical trials with targeted cancer therapeutics demonstrate that the benefit of these agents is frequently limited to small groups of patients. Moreover this benefit is often limited due to the rapid development of resistance. Thus, understanding molecular mechanisms of drug resistance will enable the rational development of treatment strategies to overcome such challenge. My research uses unbiased functional genomic tools to study cancer-relevant pathways and to guide cancer therapy. I aim to identify novel genes and networks that modulate response to cancer drugs, and to uncover genetic dependencies between the major signaling pathways in cancer that can be exploited therapeutically.